---
schema_version: "secwatch.filing_event.v1"
accession: "0000898432-23-000021"
form_type: "8-K"
ticker: "IRMD"
cik: "0001325618"
company_name: "IRADIMED CORP"
filed_at: "2023-01-19T23:59:59+00:00"
generated_at: "2026-06-20T12:57:33.294008+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# iRadimed reports preliminary Q4 revenue $14.9M (+25% YoY); issues FY2023 guidance $61M-$63M

## Summary
- Q4 2022 preliminary revenue $14.9M, up 25% YoY, above guidance of $14.1M-$14.8M.
- Sixth consecutive quarterly revenue record; orders exceeded shipments, increasing backlog.
- FY2023 guidance: revenue $61M-$63M, GAAP EPS $1.10-$1.20, non-GAAP EPS $1.23-$1.34.
- Q1 2023 guidance: revenue $14.6M-$14.9M, GAAP EPS $0.23-$0.25, non-GAAP EPS $0.26-$0.28.
- Full year 2022 revenue grew 27.5% over 2021.

## SEC filing metadata
- accession: 0000898432-23-000021
- form_type: 8-K
- ticker: IRMD
- cik: 0001325618
- company_name: IRADIMED CORP
- filed_at: 2023-01-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1325618/000089843223000021/0000898432-23-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1325618/000089843223000021/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000898432-23-000021
- JSON: https://secwatch.observer/filing/0000898432-23-000021.json
- Plain text: https://secwatch.observer/filing/0000898432-23-000021.txt

## Key facts
- Earnings Releases
  IRADIMED CORP reported the full year 2023 results: revenue $61 million to $63 million, EPS GAAP diluted earnings per share of $1.10 to $1.20, and non-GAAP diluted earnings per share of $1.23 to $1.34. Guidance initiated.
  - Period: the full year 2023
  - Revenue: $61 million to $63 million
  - EPS: GAAP diluted earnings per share of $1.10 to $1.20, and non-GAAP diluted earnings per share of $1.23 to $1.34
  - Guidance: initiated
  - Result: guidance update
  source text: For the full year 2023, the Company expects to report revenue of $61 million to $63 million, GAAP diluted earnings per share of $1.10 to $1.20, and non-GAAP diluted earnings per share of $1.23 to $1.34.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1325618/000089843223000021/0000898432-23-000021-index.htm
- Earnings Releases
  IRADIMED CORP reported the fourth quarter ended December 31, 2022 results: revenue $14.9 million.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $14.9 million
  - Result: preliminary results
  source text: Fourth-quarter revenue is expected to be approximately $14.9 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1325618/000089843223000021/0000898432-23-000021-index.htm
- Earnings Releases
  IRADIMED CORP reported the first quarter of 2023 results: revenue $14.6 million to $14.9 million, EPS GAAP diluted earnings per share of $0.23 to $0.25, and non-GAAP diluted earnings per share of $0.26 to $0.28. Guidance initiated.
  - Period: the first quarter of 2023
  - Revenue: $14.6 million to $14.9 million
  - EPS: GAAP diluted earnings per share of $0.23 to $0.25, and non-GAAP diluted earnings per share of $0.26 to $0.28
  - Guidance: initiated
  - Result: guidance update
  source text: For the first quarter of 2023, the Company expects to report revenue of $14.6 million to $14.9 million, GAAP diluted earnings per share of $0.23 to $0.25, and non-GAAP diluted earnings per share of $0.26 to $0.28.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1325618/000089843223000021/0000898432-23-000021-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.